Pyxis Oncology (PYXS) Stock Price, News & Analysis

Company Overview

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens. The company’s proprietary conjugation technology is intended to optimize drug‐to‐antibody ratios and stability in circulation, enabling more efficient tumor penetration and payload release. While most programs are currently in preclinical or Phase I development, Pyxis’s strategic approach seeks to address cancers that have historically proven resistant to standard treatments, including triple‐negative breast cancer and certain gastrointestinal malignancies.

Headquartered in Boston, Massachusetts, Pyxis Oncology conducts research and clinical activities across the United States, with plans to expand trials into Europe and Asia as programs advance. The organization draws on expertise from seasoned professionals in oncology drug discovery, translational research and clinical development. Pyxis Oncology continues to collaborate with academic institutions and contract research organizations to accelerate its mission of bringing safer, more effective cancer therapies to patients worldwide.

Key Stats

• Today's Range: $3.15 to $3.15
• 50-Day Range: $1.67 to $3.16
• 52-Week Range: $0.97 to $5.55
• Volume: 13,178 shs
• Average Volume: 767,932 shs
• Market Capitalization: $202.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Moderate Buy

Pyxis Oncology Stock Analysis - MarketRank™

Pyxis Oncology scored higher than 57% of companies evaluated by MarketBeat, and ranked 406th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Pyxis Oncology has a consensus price target of $7.50, representing about 137.3% upside from its current price of $3.16.

Amount of Analyst Coverage

Pyxis Oncology has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pyxis Oncology are expected to grow in the coming year, from ($1.19) to ($1.11) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pyxis Oncology is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pyxis Oncology is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pyxis Oncology has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.45% of the float of Pyxis Oncology has been sold short.

Short Interest Ratio / Days to Cover

Pyxis Oncology has a short interest ratio ("days to cover") of 3.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pyxis Oncology has recently increased by 42.09%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pyxis Oncology does not currently pay a dividend.

Dividend Growth

Pyxis Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.96

News Sentiment

Pyxis Oncology has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pyxis Oncology this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for PYXS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

3 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pyxis Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.70% of the stock of Pyxis Oncology is held by insiders.

Percentage Held by Institutions

39.07% of the stock of Pyxis Oncology is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 8/05/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PYXS
• CIK: 1782223
• Web: www.pyxisoncology.com
• Phone: 617-221-9059
• Fax: N/A
• Employees: 60
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Pyxis Oncology: $7.50
• High Price Target: $12.00
• Low Price Target: $5.00
• Potential Upside/Downside: +137.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79.62 million
• Net Margins: N/A
• Pretax Margin: -579.80%
• Return on Equity: -135.60%
• Return on Assets: -85.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.76
• Quick Ratio: 2.76

Sales & Book Value

• Annual Sales: $13.86 million
• Price / Sales: 14.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.86 per share
• Price / Book: 3.67

Miscellaneous

• Outstanding Shares: 63,350,000
• Free Float: 59,744,000
• Market Cap: $200.19 million
• Optionable: Optionable
• Beta: 1.31